<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effects of the <z:chebi fb="0" ids="24017">farnesyl</z:chebi> transferase inhibitor FTI-778,123 on the proliferation of <z:mpath ids='MPATH_458'>normal</z:mpath>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, and <z:mp ids='MP_0005481'>CML</z:mp> hemopoietic progenitor cells was studied </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> myeloid and erythroid progenitors are significantly more sensitive to FTI than <z:mpath ids='MPATH_458'>normal</z:mpath> progenitors while <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> myeloid progenitors may be somewhat more sensitive than <z:mpath ids='MPATH_458'>normal</z:mpath> progenitors </plain></SENT>
<SENT sid="2" pm="."><plain>In contrast, no difference between <z:mp ids='MP_0005481'>CML</z:mp> and <z:mpath ids='MPATH_458'>normal</z:mpath> progenitors are detectable </plain></SENT>
<SENT sid="3" pm="."><plain>These data strongly suggest that a trial of this agent in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and perhaps in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> is indicated </plain></SENT>
</text></document>